You have free access to this content

Clinical Liver Disease

Cover image for Clinical Liver Disease

Edited By: Michael Lucey, MD

Online ISSN: 2046-2484

Associated Title(s): Hepatology, Liver Transplantation

Recently Published Issues

See all

  • Current Issue:June 2014

    Volume 3, Issue 6

    Special Issue: Vascular Disorders

  • May 2014

    Volume 3, Issue 5

    Special Issue: Heavy Metals and the Liver

  • April 2014

    Volume 3, Issue 4

    Special Issue: Autoimmune Liver Disease, Part 4

  • March 2014

    Volume 3, Issue 3

    Special Issue: Autoimmune Liver Disease, Part 3

  • February 2014

    Volume 3, Issue 2

    Special Issue: Autoimmune Liver Disease, Part 2

Vascular Disorders in Liver Disease

Guest Edited by: Dominique Valla, M.D.

Portal Vein Thrombosis in Patients with Cirrhosis
Thomas D. Boyer, M.D., and Shahid Habib, M.D.
Portal vein thrombosis (PVT) can be seen in patients with cirrhosis in association with hepatocellular carcinoma or following splenectomy for the treatment of hypersplenism; here Drs. Boyer and Habib discuss when PVT occurs spontaneously in patients with cirrhosis.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



Management of Disordered Hemostasis and Coagulation in Patients with Cirrhosis
Nicolas M. Intagliata, M.D. and Stephen H. Caldwell, M.D.
The ultimate goal in caring for a patient with cirrhosis is to prevent bleeding before it occurs, but what if it does? Learn about therapeutics for hemostasis and approaches to procedural-related bleeding, prophylaxis, and rescue therapy in patients with liver disease.
Read the full textListen to the article presentationAnswer questions and earn CME



Noncirrhotic Nontumoral Portal Vein Thrombosis
Susana Seijo, M.D., Ph.D. and Aurelie Plessier, M.D.
Portal vein thrombosis (PVT) is one cause of extrahepatic portal venous obstruction characterized by the obliteration of the portal vein supply leading to portal hypertension. Acute or chronic PVTs are successive stages of the same disease. In the absence of recanalization, porto-portal collaterals develop, leading to a portal cavernoma. Although they share similar causes, the clinical presentation and management differs. Read, listen, or take the CME activity to learn more.
Read the full textListen to the article presentationAnswer questions and earn CME



Benign and Malignant Hepatocellular Lesions in Patients with Vascular Liver Disease
Valerie Vilgrain, M.D., Pierre-Emmanuel Rautou, M.D., PhD, Valerie Paradis, M.D., and Maxime Ronot, M.D., PhD
Benign and Malignant Hepatocellular Lesions in Patients with Vascular Liver Disease
Learn to distinguish the features of common vascular liver diseases which induce hepatocellular tumors, including Budd-Chiari Syndrome, Hereditary Hemorrhagic Telangiectasia, and others.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



Diagnosis of Thrombophilia/Prothrombotic Conditions in Patients with Liver Disease
Massimo Primignani, M.D., and Vincenzo La Mura, M.D., Ph.D.
Thromboses of splanchnic veins are encountered increasingly by clinicians, either as a complication of chronic liver disease or as the first presentation of a primary form of vascular liver disease. Learn how to make the right diagnosis with Dr. Primignani and La Mura.
Read the full text.Listen to the article presentation.Answer questions and earn CME.

Series on New Treatments for Hepatitis C

Guest Edited by Donald M. Jensen, M.D., F.A.C.P.


New All-Oral HCV Therapies for Genotype 1: A Final Good-bye to Interferon
Anna S.F. Lok, M.D.
With more than 30 direct-acting antiviral agents (DAAs) in clinical trials, the hepatitis C community anticipates that the right combinations of DAAs will emerge, permitting treatment of hepatitis C virus (HCV) genotype 1 with interferon (IFN)-free regimens.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



New AASLD/IDSA HCV Practice Guidelines: An Online Resource
Gary L. Davis, M.D.
As treatment for Hepatitis C rapidly evolves, how are recommendations being developed, and how they will be updated over time? Read or listen to Dr. Gary Davis' review to learn more about how organiziations like the AASLD are working to keep clinicians informed with the best and most up-to-date guidelines.
Read the full textListen to the article presentationAnswer questions and earn CME



Recent FDA Approval of Sofosbuvir and Simeprevir. Implications for Current HCV Treatment
M. Valerie Lin, M.D., and Raymond Chung, M.D.
Drs. Lin and Chung break down what clinicians need to know about Sofosbuvir and Simeprevir: from mechanisms of action, to approved indications, use outside approved indications, and treatment challenges.
Read the full textListen to the article presentationAnswer questions and earn CME

Test your knowledge! Use the Hepatitis C Self Assessment to complete board-style practice questions.

More from Vascular Disorders in Liver Disease

Noncirrhotic Intrahepatic Portal Hypertension
Vijay Bodh, M.D. and Yogesh Chawla, M.D.
Noncirrhotic Intrahepatic Portal Hypertension
Drs. Bodh and Chawla review the etiology, pathogenesis, presentation, diagnosis, natural history, and management of noncirrhotic intrahepatic portal hypertension.
Read the full text.Listen to the article presentation.Answer questions and earn CME.



Budd-Chiari Syndrome
Pierre-Emmanuel Rautou, M.D., Ph.D.
Review the definition, causes, clinical and laboratory features, treatment, and other issues in BCS.
Read the full text.Listen to the article presentation.Answer questions and earn CME.



iTunes logo

Access CLD on the go.
Listen to the author interviews and readings of the full articles by subscribing to the iTunes podcast.



Find CLD on Facebook

Follow CLD on Twitter

SEARCH

SEARCH BY CITATION